Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for TransMedics Group, Inc. (TMDX : NSDQ)
 
 • Company Description   
TransMedics Inc. is a commercial-stage medical technology company. It is engaged in transforming organ transplant therapy for end-stage organ failure patients. The company offers Organ Care System, an integrated, compact, portable preservation technology which addresses unmet need for organs for transplantation. TransMedics Inc. is headquartered in Andover, Massachusetts.

Number of Employees: 728

 
 • Price / Volume Information   
Yesterday's Closing Price: $111.50 Daily Weekly Monthly
20 Day Moving Average: 1,199,364 shares
Shares Outstanding: 33.82 (millions)
Market Capitalization: $3,771.40 (millions)
Beta: 1.91
52 Week High: $177.37
52 Week Low: $55.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 38.37% 31.12%
12 Week 54.47% 66.89%
Year To Date 78.83% 85.83%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
200 MINUTEMAN ROAD
-
ANDOVER,MA 01810
USA		 ph: 978-552-0900
fax: -		 investors@transmedics.com http://www.transmedics.com
 
 • General Corporate Information   
Officers
Waleed H. Hassanein - President; Chief Executive Officer; Director
James R. Tobin - Chairman
Gerardo Hernandez - Chief Financial Officer and Treasurer
Edward M. Basile - Director
Thomas J. Gunderson - Director

Peer Information
TransMedics Group, Inc. (ABMD)
TransMedics Group, Inc. (DMDS)
TransMedics Group, Inc. (CPWY.)
TransMedics Group, Inc. (EQUR)
TransMedics Group, Inc. (ECIA)
TransMedics Group, Inc. (FMS)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 89377M109
SIC: 3845
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/30/25
Share - Related Items
Shares Outstanding: 33.82
Most Recent Split Date: (:1)
Beta: 1.91
Market Capitalization: $3,771.40 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.39 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $1.56 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/30/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 71.40
Trailing 12 Months: 81.99
PEG Ratio: -
Price Ratios
Price/Book: 14.16
Price/Cash Flow: 67.76
Price / Sales: 7.72
EPS Growth
vs. Year Ago Period: 100.00%
vs. Previous Quarter: 268.42%
Sales Growth
vs. Year Ago Period: 48.21%
vs. Previous Quarter: 18.02%
ROE
03/31/25 - 21.88
12/31/24 - 18.00
09/30/24 - 18.74
ROA
03/31/25 - 6.15
12/31/24 - 4.62
09/30/24 - 4.39
Current Ratio
03/31/25 - 9.10
12/31/24 - 8.30
09/30/24 - 8.20
Quick Ratio
03/31/25 - 8.32
12/31/24 - 7.52
09/30/24 - 7.33
Operating Margin
03/31/25 - 10.03
12/31/24 - 8.03
09/30/24 - 8.14
Net Margin
03/31/25 - 10.03
12/31/24 - 8.03
09/30/24 - 8.14
Pre-Tax Margin
03/31/25 - 10.25
12/31/24 - 8.10
09/30/24 - 8.14
Book Value
03/31/25 - 7.87
12/31/24 - 6.81
09/30/24 - 6.25
Inventory Turnover
03/31/25 - 4.15
12/31/24 - 3.66
09/30/24 - 3.37
Debt-to-Equity
03/31/25 - 1.92
12/31/24 - 2.23
09/30/24 - 2.42
Debt-to-Capital
03/31/25 - 65.70
12/31/24 - 69.02
09/30/24 - 70.78
 

Powered by Zacks Investment Research ©